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Deborah L. Strong, James C. Price, and A.C. Capomacchia
Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy; The University of Georgia, Athens, GA, USA
Theophylline controlled release capsules (THEO-24 CR)
were used as a model system to evaluate accelerated dissolution
tests for process and quality control and formulation develop-
ment of controlled release formulations. Dissolution test acceler-
ation was provided by increasing temperature, pH, flow rate, or
adding surfactant. Electron microscope studies on the theophyl-
line microspheres subsequent to each experiment showed that at
pH values of 6.6 and 7.6 the microspheres remained intact, but at
pH 8.6 they showed deterioration. As temperature was increased
from 37–57°C, no change in microsphere integrity was noted.
Increased flow rate also showed no detrimental effect on integ-
rity. The effect of increased temperature was determined to be
the statistically significant variable.
Keywords accelerated flow through dissolution, pH, temperature,
flow rate, theophylline
INTRODUCTION
The objective was to develop an accelerated dissolu-
tion test for controlled release formulations for quality and
process control, and formulation development. Reproduc-
ible dissolution testing has long been recognized as
extremely important for quality control.
In this study, theophylline controlled release capsules
(THEO-24 CR) were used as a model drug system. The vari-
ables of temperature, pH, and flow rate for aqueous dissolu-
tion medium were examined; the effect of adding surfactant
(sodium lauryl sulfate) to the medium was also evaluated
using the flow-through cell method (USP Apparatus IV).
The test criteria were that it be substantially shorter than the
USP eight-hour test, and that it correlated with USP specifi-
cations for products labeled for dosing every 24 h as
described in USP Monograph test 6 for products labeled for
dosing every 24 h.[1] The specific goal was to attain USP
acceptable theophylline release in less than three hours in
order to make the accelerated test a viable alternative for pro-
cess and quality control, and formulation development.
THEO-24 CR was chosen as the model drug since as an
extended release product it is a suitable dosage form for flow
through dissolution testing and therefore, to evaluate acceler-
ated flow through dissolution.[2–9] Moreover, the flow
through test, initially developed in FDA laboratories 40
years ago, has been reported to offer the best discrimination
due to manufacture or product composition changes.[2–4]
Two studies report on accelerated dissolution testing
for process and quality control and formulation develop-
ment of controlled release formulations. The goals were to
substantially reduce testing time compared to USP
requirements. The first used increased temperature to
accelerate dissolution from a controlled release Roxiam
formulation in a USP IV flow through apparatus. Analyti-
cal times were reported to be less than 30 min for one
assay.[10] The second study used increased temperature,
solvent and stirring to accelerate dissolution of USP sali-
cylic acid calibrator tablets in a USP II apparatus. Dissolu-
tion times could be accelerated by a factor of 5 which
meant that a single analysis could be performed in less
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10 J.W. Collier et al.
than one hour.[11] Both of these ground-breaking studies
showed that substantial time could be saved using the
‘Accelerated Dissolution Rate Analysis’ (ACDRA)
method with no loss in correlation compared to the stan-
dard USP test. Further discussions on the possibility of
using increased temperature to accelerate the dissolution
process, and the use of surfactants and hydroalcoholic
media have also been reported.[12,13]
MATERIALS AND METHODS
Materials
The following materials were obtained from the com-
mercial suppliers below and used without further purifica-
tion. Theophylline (mw 180.16) as THEO-24 Controlled
Release capsules (100 mg) from Wal-Mart Pharmacy,
Athens, GA, USA; acetonitrile, ammonium hydroxide,
sodium acetate trihydrate, from Sigma-Aldrich Chemicals,
St Louis, MO, USA; glacial acetic acid, potassium phos-
phate monobasic, hydrochloric acid, and sodium hydrox-
ide from Aldrich Chemicals, Milwaukee, WI, USA;
methanol and sodium lauryl sulfate (SLS; powder/NF/
FCC) from Fisher Chemicals, Fairlawn, NJ, USA; Theo-
phylline RS Anhydrous (USP) from Spectrum Chemical
Manufacturing Corporation, New Brunswick, NJ, USA.
Instruments
Spectronic 2000 Spectrophotometer, Bausch and
Lomb, NJ; Thermo Spectronic Helios Aquamate, Roches-
ter, NY; Haake E-52 Water Bath, Haake Instruments, Inc.,
Saddle Brook, NJ; Sigma Motor Peristaltic Pump Model
T8, Middleport, NY, USA.
UV Spectrophotometric Studies
UV Spectrophotometric analyses for all samples were
conducted at 271 nm, the uv maximum for theophylline
using a 10 mm quartz at 25°C. Absorbance standard
curves were constructed using solutions of reference stan-
dard Theophylline RS Anhydrous (USP) in either phos-
phate buffer dissolution medium (0.05M) at the indicated
pH values; 0.05 M phosphate buffer at pH 1.2 and 7.6 with
SLS at 25°C; theophylline samples were prepared at per-
cent concentrations from 5–100%. The absorbance versus
percentage concentration plots for Theophylline RS were
linear over this concentration range and were used to
determine the percent drug released in all dissolution
samples at 25°C.
Dissolution Method
In vitro dissolution studies of THEO-24 CR capsules
were conducted in triplicate; a sample was withdrawn at
each time point in three separate experiments using the
flow-through cell method (USP Apparatus IV). Samples
of 4 mL were withdrawn every 30 min for 3 h; the 4 mL
sample removed was immediately replaced with 4 mL of
fresh dissolution medium (either phosphate buffer, or
phosphate buffer with SLS). Dissolution profiles of Per-
cent Released versus Time (n = 3) were constructed as
shown in Figures 1–4. Medium temperature, pH and flow
rate were changed to evaluate the effect on release rate.
One hundred milligrams of THEO-24 CR micro-
spheres were introduced into the flow cell. Dissolution
media (1000 mL) pH was altered depending on experi-
ment requirements. Phosphate buffer 0.05 M was adjusted
to the desired pH by adding small increments of 1M
NaOH. Samples were withdrawn from the media reservoir
at the predetermined time intervals stated above. The per-
cent concentration of dissolved Theophylline in each sam-
ple was measured spectrophotometrically at 271 nm
against a reference cell containing only the dissolution
medium.
Flow-Through Dissolution
The flow-through cell, of transparent and inert mate-
rial, was mounted vertically containing a filter system that
prevented escape of undissolved particles from the top of
the cell; standard cell diameter was 12 mm; the bottom
cone was filled with small glass beads of about 1 mm
diameter with one bead of about 5 mm positioned at the
apex to protect the fluid entry tube.[1] The flow-through
cell used had three parts: the lower cone, the middle cylin-
drical portion, and the filter head on top. The cone is sepa-
rated from the cylindrical portion by a #40 mesh screen
and a microfiber filter; the filter head also holds a glass
microfiber filter. The entire cell is immersed in a water
bath with the temperature maintained at 37, 47, or 57 ±
0.5ºC as per experiment requirements; and the dissolution
medium is kept at the corresponding bath temperature for
each experiment. All experiments were conducted in a
closed loop setup. Flow rates of the dissolution medium
through the cells were within USP specifications of 4, 8,
and 16 mL/min.
Electron Microscope Study
Microspheres were dried 24 h at 50°C then placed
in a dessicator for 48 h at room temperature before
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Accelerated Dissolution Testing for Controlled Release Microspheres 11
being submitted for electron microscopy imaging at the
UGA Electron Microscopy Laboratory as shown in
Figures 5–11. 
Process Variables
To determine the influence of the process variables
pH (A), temperature (B) and flow rate (C), a two-level
3 factor (23) factorial design was selected. Standard
runs were generated for times 0.5, 1.0, and 1.5 h, as
shown in Table 1 for 0.5 h, but not for times 2.0–3.0 h
since Theophylline release ended at about 1.5 h at
higher temperatures. Pareto charts were constructed for
experimental runs; the chart for 0.5 h is shown in
Figure 12. The factorial design and analyses were gen-
erated using Stat-Ease Design-Expert Version 7.0.3
(Stat-Ease Inc., Minneapolis, MN, USA). 
Figure 1. Dissolution profiles of Theo 24-CR in phosphate buffer 0.05M; flow rate 4 mL/min. Temperature (pH/r2): 37°C
(6.6/0.9776, 7.6/0.9932, 8.6/0.9977); 47°C (6.6/0.9928, 7.6/0.9958, 8.6/0.9856); 57°C (6.6/0.9944, 7.6/0.9902, 8.6/0.9761); n = 3.
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RESULTS AND DISCUSSION
Dissolution Profiles
The process variables associated with flow through
dissolution testing: temperature, pH, and flow rate were
manipulated to assess the potential for accelerated dissolu-
tion testing. In this study, the drug release of commercially
available theophylline microspheres (THEO-24 CR) was
determined using a flow-through cell apparatus (USP
Apparatus IV) at three different flow rates, 4, 8, and 16
mL/min; three different pH values, 6.6, 7.6, and 8.6;
and three temperatures, 37, 47, and 57°C. Figures 1–4
show the linear dissolution profiles and regression coef-
ficients upon changing these variables, which closely
resemble those published by Macheras et al. for
Theo-Dur under comparable conditions.[6,14] The most
benign parameters for the current study were pH 7.6,
Figure 2. Dissolution profiles of Theo 24-CR in phosphate buffer 0.05M; flow rate 8 mL/min. Temperature (pH/r2): 37°C (6.6/
0.9871, 7.6/0.9971, 8.6/0.9948); 47°C (6.6/0.9847, 7.6/0.9901, 8.6/0.9811); 57°C (6.6/0.9921, 7.6/0.9935, 8.6/0.9835); n = 3.
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Accelerated Dissolution Testing for Controlled Release Microspheres 13
37°C, and flow rate 8 mL/min showing 55% linear drug
release in 3 h (Figure 2). The addition of 0.1% SLS to
the same solution increased drug release from 55–65%
in 3 h (Figure 4). Dissolution under these conditions
correlates with USP test 6 which provides for 55–75%
release of theophylline within 8 h for products labeled
for dosing every 24 h. Fastest drug release occurred at
57°C at flow rates of 8 and 16 mL/min at which point
85% of the theophylline was linearly released in 1.5 h
from solutions at pH 7.6 and 8.6, also meeting the USP
requirements (Figures 2 and 3). These results compare
with those of Zackrisson et al., where a flow through
apparatus was employed using increased medium tem-
perature to accelerate dissolution rate of remoxipride
microcapsules.[10] Their results indicate that the time
needed for one analysis of Roxiam takes less than 5%
of the time required for the USP method; estimated to
be about one hour. They report a direct correspondence
between their data recorded at 85°C with USP data
recorded at 37°C with no mention of microsphere
Figure 3. Dissolution profiles of Theo 24-CR in phosphate buffer 0.05M; flow rate 16 mL/min. Temperature (pH/r2): 37°C (6.6/
0.9938, 7.6/0.9851, 8.6/0.9943); 47°C (6.6/0.9808, 7.6/0.9966, 8.6/0.9965); 57°C (6.6/0.9755, 7.6/0.9926, 8.6/0.9962); n = 3.
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Figure 4. Dissolution profiles of Theo 24-CR at 37°C, in phosphate buffer at pH 1.2 (r2: 0.9924); and 7.6 (r2: 0.9973) with SLS
(0.1%) compared to pH 7.6 (r2: 0.9965), in buffer alone, n=3.
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Figure 5. Electron micrograph of intact theophylline microspheres
before dissolution.
Figure 6. Electron micrograph of microspheres after dissolution
at 37°C, pH 6.6, 8 mL/min flow rate.
Figure 7. Electron micrograph of microspheres after dissolution
at 37°C, pH 7.6, 8 mL/min flow rate.
Figure 8. Electron micrograph of microspheres after dissolution
at 37°C, pH 8.6, 8 mL/min flow rate.
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Accelerated Dissolution Testing for Controlled Release Microspheres 15
integrity. However, the reported correspondence with
USP data strongly indicates little or no loss in integrity.
The data we present here convincingly show that
increased drug release at 57°C, causes no apparent
change in microsphere integrity as shown in the elec-
tron micrograph, Figure 10, at pH 7.6, or observed as
change in linearity of release in Figures 2 and 3. Based
on these results, the results of Zackrisson et al., and
those of Quist and Ostling, increasing temperature
should be considered first as a method for accelerating
drugs release from microspheres constructed with poly-
mers responsive to temperature.[10,11,15,16] Further, the
Pareto chart in Figure 12 indicates temperature as the
significant variable for theophylline release in the cur-
rent study. The Pareto Charts were generated from data
obtained from three standard 23 factorial runs at 0.5,
1.0, and 1.5 hours; Figure 12 is for the 0.5 h time point.
They were statistically analyzed to determine the sig-
nificance of the process variables pH (A), temperature
(B), and flow rate (C) on theophylline release.[17] The
chart in Figure 12 presents as a vertical bar graph in
which the height of the bars are proportional to the
value of the estimated effects of the three variables,
temperature, pH or flow rate, as well the effects of
interacting variables AB, AC, or ABC. Bars above the
first dotted line (T-Value Limit) are most likely signifi-
cant. Bars below it are not likely to be significant. Bars
above the Bonferroni line are almost certainly signifi-
cant but must be confirmed by ANOVA. For timepoints
0.5, 1.0, and 1.5, ANOVA calculates P-values of
0.0057, 0.169, and 0.0045, respectively, indicating the
significance of the variable temperature on theophylline
released from the microspheres. The effects of variables
pH and flow rate ranked 2, and 3, respectively, were not
statistically significant as were the effects of the inter-
active variables, even though flow rate and pH appear
to increase drug release as seen in Figures 1–4.
Figure 9. Electron micrograph of microspheres after dissolution
at 47°C, pH 6.6, 8 mL/min flow rate.
Figure 10. Electron micrograph of microspheres after dissolution
at 57°C, pH 7.6, 8 mL/min flow rate.
Figure 11. Electron micrograph of microspheres after dissolution
at 37°C, pH 7.6, 8 mL/min flow rate and containing 0.1% sodium
lauryl sulfate.
Table 1 
Standard 23 factorial run at time 0.5 hours for the three factors 
pH, temperature, and flow rate at two levels
Std Run
Factor 1 
A: pH
Factor 2 
B: Temp
Factor 3 
Flow rate
Response % 
Theo released
3 1 6.6 57 4 12
5 2 6.6 37 16 4
1 3 6.6 37 4 3
4 4 8.6 57 4 13
6 5 8.6 37 16 8
2 6 8.6 37 4 5
7 7 6.6 57 16 14
8 8 8.6 57 16 29
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Electron Micrographs
Figures 5–11 show representative electron micro-
graphs of Theo-24 CR microspheres after dissolution
testing and how their physical appearance is altered
after changing the variables, pH, temperature, and sur-
factant. Figure 5 shows intact microspheres before dis-
solution which are similar to microspheres after
dissolution at pH 6.6, 37°C and 8 mL/min flow rate
(Figure 6). Microspheres at pH 8.6 appear degraded
compared to those at pH 6.6 and 7.6 (Figures 6, 7, 8).
However, the apparent degradation did not adversely
affect drug release or cause a dose dumping effect since
theophylline release remained linear and zero order
(Figures 1–3). The effect of pH on increasing drug
release is also shown in Figures 1–3; even though not
statistically significant the increase may reflect changes
in theophylline ionization upon changing the medium
from pH 6.6–8.6. In aqueous media of pH 8.6 theophyl-
line (pKa 8.77) is almost 50% ionized to the conjugate
base suggesting that a relatively minor pH related solu-
bility effect may be causing increased drug release.
This view supported by the results shown in the Pareto
charts where pH is ranked second in effects but is not
significant. It is clear that increased temperature does
not alter microsphere integrity upon comparing Figures
7, 9, and 10 as previously discussed.
Surfactant
Adding sodium lauryl sulfate (0.1%) to the buffer
medium at 37°C, pH 7.6, and flow rate 8 mL/min
increased drug release by roughly 20% at the three hour
mark as shown in Figure 4 with no loss of microsphere
integrity as seen in Figure 11. Moreover, when compared
to data in Figure 4, addition of surfactant results in even
greater drug release than elevating medium pH to 8.6. A
recent study showed that 1% sodium lauryl sulfate
increased carbamazepine from controlled release tablets
fourteen fold.[18]
Upon review of this article it was noted that potas-
sium salts (from the potassium phosphate buffer) pre-
cipitate SLS by forming the relatively insoluble
potassium lauryl sulfate (PLS; solubility at room tem-
perature about 0.02%).[19,20] This is a dynamic equilib-
rium and the effect of PLS formation is nullified by
increasing concentrations of SLS.[21] PLS solubility has
been reported to be temperature dependent such that at
37°C its solubility is about 0.11%.[20] The current study
used SLS at 0.1% concentration and potassium ion con-
centration was about 0.6% from the buffer solution.
Therefore PLS could only form to the extent of its solu-
bility at 37°C, and for this reason PLS solubility or pre-
cipitation was not a factor in the results presented in
Figure 4 of the current study.
Figure 12. Pareto chart: t-Value of [Effect] versus Rank, at time point 0.5 hours for percentage release of theophylline for the effect
of variables ranked according to significance: B, Temperature (rank 1); pH, A (rank 2); Flow Rate C, (rank 3); and interactions AB
(rank 4); AC (rank 5); BC (rank 6); ABC (rank 7).
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CONCLUSIONS
Accelerated dissolution testing of theophylline–24
CR capsules using USP Apparatus IV may be attained by
increasing medium temperature, pH, increasing flow rate,
and adding a surfactant; however only the effect of tem-
perature is significant. Increasing dissolution medium
above pH 7.6–8.6 caused a loss of microsphere integrity.
The most benign parameters for the current study were pH
7.6, 37°C, and flow rate 8 mL/min showing 55% linear
drug release in 3 h. Addition of the surfactant sodium lau-
ryl sulfate increased the maximum drug released in 3 h to
65%. Dissolution under both of these conditions correlates
with USP test 6 which provides for 55–75% release of
theophylline in 8 h for products labeled for dosing every
24 h. Fastest drug release (85%/1.5 h) occurred at 57°C,
pH 7.6 or 8.6, and flow rate either 8 or 16 mL/min. A com-
bination of increased medium temperature and added sur-
factant may prove to be the optimal conditions for
accelerated drug release of controlled release formulations
while maintaining microsphere integrity.
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